Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangqijishengtang is a Traditional Chinese Medicine (TCM) herbal formula primarily composed of *Astragalus membranaceus* (Huangqi) and *Taxillus chinensis* (Sangjisheng). It is specifically indicated for the treatment of rheumatoid arthritis and associated bone metabolism disorders, such as osteopenia, particularly in patients presenting with the TCM syndrome of "liver and kidney deficiency." The formula is designed to strengthen the musculoskeletal system, improve bone mineral density, and alleviate joint inflammation. Clinical evaluation, including trial ChiCTR2100042329 sponsored by The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine, focuses on its ability to regulate bone metabolism and inflammatory markers in RA patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huangqijishengtang.